Carl read the papersWhat it actually is
PEGylation means attaching a polyethylene glycol chain to a molecule. It is standard pharmaceutical practice and it works: the chain makes the molecule bigger, slows how fast the kidneys clear it, and shields it from enzymes. Several approved medicines are PEGylated.
PEG-MGF applies that trick to the 24-amino-acid MGF peptide. The commercial pitch is the same pitch as MGF, plus longer exposure. The catch is that the biology being cited was measured on the unmodified peptide, and a 2026 review in Front Endocrinol makes the point directly: PEGylation fundamentally alters pharmacokinetics and tissue exposure, so effects seen with native IGF-1Ec or isolated E-domain peptides cannot be assumed to carry over.
How it’s thought to work
- Borrowed mechanism — Every mechanism claimed for PEG-MGF is an MGF mechanism: satellite cell proliferation, delayed differentiation, local repair after mechanical damage. None of it was measured on the PEGylated version.
- Longer exposure — The pegylation is meant to extend circulating time. The 2026 review notes that no peer-reviewed study has reported the half-life of this product, or even the route of administration used.
- A receptor still missing — The original E-domain work argued for a receptor separate from the IGF-1 receptor. Nobody has identified it, and a 2016 receptor assay found human MGF produced no IGF-1 receptor activation at all.
- Local versus systemic — The animal repair studies that get quoted delivered peptide into the injured tissue. A long-acting systemic version is a different proposition, which is exactly the gap the review flags.
What the research says
There is no peer-reviewed human study of PEG-MGF. The 2026 Front Endocrinol review of GH and IGF-1 axis performance peptides sorted every compound it covered into evidence tiers, and placed PEG-MGF in tier D, the bottom one: no peer-reviewed human studies, supported only by preclinical extrapolation and grey-literature user narratives. It also notes no published route of administration and no reported half-life. The underlying MGF literature it extrapolates from is itself contested: in 2014 two pharmaceutical companies failed to reproduce the muscle-cell effect at concentrations up to 500 ng/ml. So the evidence chain runs from an unreplicated cell finding, through animal injury models using local delivery, to a chemically different product that nobody has studied. Each link is weaker than the one before it.
- Tier D in the 2026 Front Endocrinol review: no peer-reviewed human studies at all.
- No published half-life and no published route of administration for the PEGylated product.
- All cited biology comes from the unmodified MGF peptide or the IGF-1Ec splice variant, not from PEG-MGF.
- The key MGF cell experiment failed to reproduce in 2014 at two pharmaceutical companies.
- The review flags a theoretical proliferative concern, based on IGF-1Ec expression in cancer biology.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Human dose | Not established. No human study exists, so no dose, no interval and no ceiling can be stated. |
| Why there is no number | A dose needs someone to have given a known amount to people and measured what happened. For PEG-MGF nobody has, and the pharmacokinetics that would let you reason toward one have not been published either. The 2026 review says plainly that no peer-reviewed human study has even reported the route of administration, and that the half-life is not reported. |
| Reported online | People do post about using it. Going back to 2014 the figures cluster in the low hundreds of micrograms per injection, a few times a week, and the spread runs well beyond that in both directions. These are self-reports with nothing behind them, they disagree with each other, and some long-term users say it did nothing at all. Treat them as a record of what people do, not as a dose. |
| Dosing figures in the literature | The 2026 review does tabulate figures taken from bodybuilding forums, and labels them explicitly as anthropological and behavioural material documenting dosing beliefs, not evidence of efficacy or safety, and not to be read as clinical guidance. Carl takes the authors at their word. |
| Batch to batch | Pegylation is a manufacturing step, not part of the sequence. Two vials with the same label can carry different chain lengths and different degrees of attachment, which is another reason a number would not transfer anyway. |
| Carl's position | Not established means not established. A figure off a forum makes the page look more useful and the reader less safe. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Understanding the product category | a chemically modified version of a peptide whose own evidence failed replication |
| Spotting borrowed evidence | the research quoted on sales pages is MGF research, not PEG-MGF research |
| Sport eligibility | mechano growth factors sit under S2.3 of the WADA list, prohibited at all times |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
No administration guide here. The honest reason: there is nothing to base one on, and the product is chemically different from the peptide whose research is used to sell it. Two points are worth more than a protocol. First, PEGylation changes where a molecule goes and how long it stays, so a long-acting systemic version of a peptide studied by local delivery into injured tissue is not the same experiment. Second, the IGF-1 pathway is a growth pathway, and the 2026 review lists a biologically plausible but unproven mitogenic concern for this class. Anyone considering it for an injury is better served by a sports physician and a diagnosis.
Stacks it appears in
- With IGF-1 LR3 — sold as a pairing. The same 2026 review puts both in tier D, so the stack combines two compounds with no human evidence between them.
- With GH secretagogues — ipamorelin, CJC-1295 and the GHRPs appear in the same protocols. Those at least have phase I human data, which PEG-MGF does not.
- With BPC-157 or TB-500 — the injury stack. SAHPRA names both as examples of illegally marketed peptides, and TB-500 is named on the WADA list as well.
Sources
- Dominikowski A et al. 2026, Front Endocrinol. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis (PMID 42395176, PMC13322892)
- Fornaro M et al. 2014, Am J Physiol Endocrinol Metab. MGF peptide has no apparent effect on myoblasts or primary muscle stem cells (PMID 24253050)
- Janssen JA et al. 2016, PLoS One. Potency of full-length MGF to induce maximal activation of the IGF-I R (PMID 26991004)
- Matheny RW et al. 2010, Endocrinology. Minireview: Mechano-growth factor (PMID 20130113)
- Peña JR et al. 2015, Biomaterials. Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction (PMID 25678113)
- Thevis M et al. 2014, Growth Horm IGF Res. Mass spectrometric characterization of a biotechnologically produced full-length MGF relevant for doping controls (PMID 25466910)
- WADA 2026 Prohibited List, S2.3 growth factors
- SAHPRA, Peptide Products: Public Information (May 2026)
- ClinicalTrials.gov search: PEG-MGF
